These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 7597425

  • 1. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer.
    Sledge GW, Robert N, Sparano JA, Cogleigh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill-Stevens W.
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):105-8. PubMed ID: 7597425
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW, Robert N, Sparano JA, Cobeligh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill-Stevens W.
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
    [Abstract] [Full Text] [Related]

  • 3. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW.
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):123-5; discussion 126-9. PubMed ID: 7481854
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA.
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P, Gehl J, Boesgaard M, Jensen TP, Jensen BW, Ejlertsen B.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ, Millenson M, Rosvold E, Litwin S, McAleer CA, Bonjo CA, Ozols R.
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
    Sledge GW.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.